Feature

There is great potential for the women’s reproductive disorders therapeutics market – can you maximise your company’s potential in this growing market?



The systemic hormonal contraceptive market is currently a $7bn market, with hormonal oral contraceptives dominating the market for many years. However, oral pills are increasingly facing competition from other routes of delivery. With patent expiration, several companies have begun manufacturing generic products. Hormonal contraceptives for women have become the benchmark for the safety and effectiveness of birth control methods.



Although hormonal contraceptives are already a very mature market, visiongain believes that there is still room for further growth. In addition, modern basic research has identified some completely new approaches for the contraceptives of the future. Hormonal oral contraceptives will continue to play an important role in birth control from 2008 to 2018.



The hormonal oral contraceptive market is undergoing both lifecycle management and product line extension of existing products in the market. There are progestin-only preparations and combined preparations containing an oestrogen and a progestin. Bayer Schering is developing a pill containing various forms of progestin. Clinical studies show that the new drospirenone pill has an apparent therapeutic effect on premenstrual dysphoria - a particularly severe form of the premenstrual syndrome (PMS), as well as on acne. Pills are increasingly being developed with reduced oestrogen dosages.



Menopause and Hormone Replacement Therapy HRT has been the subject of considerable discussion and in light of recent studies, visiongain provides comprehensive market information on HRT market prospects from 2008 to 2018.



Women’s Reproductive Disorders Therapeutics, 2008-2018 examines the market critically, through comprehensive primary and secondary research. In addition to consultation with industry opinion, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based study with detailed financial analyses and informed opinion on the future of the women’s reproductive health market.




In Women’s Reproductive Disorders Therapeutics, 2008-2018 you will receive the following essential information for understanding the women’s reproductive disorders therapeutics market and industry:

• The value of the women’s reproductive disorders therapeutics market and its principal market segments from 2008 to 2018


• Which current or future therapies that will drive the market for women’s reproductive disorders therapeutics from 2008 to 2018, with detailed sales forecasts


• Market drivers and restraints, including a comprehensive SWOT analysis for women’s reproductive disorders therapeutics


• The companies shaping the market and their business strategies

• Business managers of pharmaceutical industry related to women’s reproductive disorders therapeutics


• Researchers, analysts and academics interested in women’s reproductive disorders therapeutics


• Senior staff in healthcare authorities relevant to women’s reproductive disorders therapeutics


• Investors in the pharmaceutical industry relevant to women’s reproductive disorders therapeutics


• Other interested business managers of multinational companies relevant to women’s reproductive disorders therapeutics


• Other business managers of domestic companies


• Academics, researchers and media

• Full searchable report when you buy the company or corporate editions


• Copies can be printed conveniently for offline reading


• Expert opinion from industry sources


• Packed with analysis, figures, graphs and tables.

Licence Options

Single User £1,499.00 5 User Licence £2,999.00 Company wide Licence £4,999.00